About ▼ Careers Internship MedBlog Contact us

LOGIN REGISTER

Medindia » News » Drug News » New Drug Slashes Heart Attack, Stroke Risk in Diabetics

New Drug Slashes Heart Attack, Stroke Risk in Diabetics

by VR Sreeraman on Jun 29 2012 9:01 PM

New Drug Slashes Heart Attack, Stroke Risk in Diabetics

A new drug may prevent heart attack risk in patients with type 2 diabetes, finds a research.

The revolutionary new treatment could help thousands of patients who do not respond to the commonly used first-line treatment, metformin, the Daily Express reported.

Type 2 Diabetes - Risk Factors - Symptoms & Signs - Management - Prevention

Type 2 Diabetes - Risk Factors - Symptoms & Signs - Management - Prevention
Globalization and changing lifestyles has made diabetes very common in developing countries so much so that India is known as the Diabetes Capital of the World.

Metformin can become ineffective in the long term for many patients, according to an article published online in The Lancet.

Patients are then offered a class of drugs that is known as sulphonylureas in addition.

However, these drugs can lead to low blood sugar levels that is known as hypoglycaemia, and weight gain, putting patients at increased risk of heart attack and stroke.

Diabetes Essentials: Types, Complications, Management & Treatment

Diabetes Essentials: Types, Complications, Management & Treatment
Diabetes is a metabolic disease caused by insulin deficiency that leads to high blood sugar levels and several associated complications if left untreated.

The new drug, linagliptin, results in significantly less weight gain and also less hypoglycaemia, experts from Tubingen University Hospital, in Germany, has found.

Source-ANI

Diabetes Foot Care Treatment Prevention

Diabetes Foot Care Treatment Prevention
Valuable information on diabetic foot care, treatment and prevention.

Diabetes Type 2 - New Once a Day Drug Linagliptin Approved by FDA

Diabetes Type 2 - New Once a Day Drug Linagliptin Approved by FDA
New drug gives another treatment option for the millions of people with type 2 diabetes. linagliptin (Tradjenta), a once-daily pill for type -II diabetes has now been approved.

Recommended Readings

Type 2 Diabetes

Type 2 Diabetes

Globalization and changing lifestyles has made diabetes very common in developing countries so much so that India is known as the Diabetes Capital of the World.

Aphasia

Aphasia is a condition where the patient has a language disorder. The patient has problems with comprehension, expression, repetition, reading and writing.

Red Flag Symptoms You Must Never Ignore

Red Flag Symptoms You Must Never Ignore

Any deviation from normal health can cause symptoms, some of which are ominous and need immediate attention.

Mitral Valve Stenosis And Mitral Valve Replacement

Mitral Valve Stenosis And Mitral Valve Replacement

Mitral valve replacement is a surgical heart procedure to correct either the narrowing (stenosis) or the leakage (regurgitation).

Drug Toxicity

Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a drug, reaction to a drug or drug abuse.

Mitral Valve Prolapse

Mitral Valve Prolapse

Mitral Valve Prolapse is a relatively common condition and causes leakage of blood through the valve. MVP is not life-threatening in most instances.

Latest Drug News

US FDA Approval of N-803: Ray of Hope For Bladder Cancer Patients

US FDA Approval of N-803: Ray of Hope For Bladder Cancer Patients

The US FDA approves a immunotherapy drug, N-803, for BCG-unresponsive non-muscle invasive bladder cancer, suggested to be used in conjunction with BCG.

Resmetirom For MASH: Approved by US FDA, Increase in Partnerships

Resmetirom For MASH: Approved by US FDA, Increase in Partnerships

The increasing trend in strategic partnerships between innovator companies, and the US FDA approval for Rezdiffra has led to a boost in the development of medications for MASH.

Semaglutide: A Dominant Player for Patients With Heart Failure

Semaglutide: A Dominant Player for Patients With Heart Failure

Data provesSemaglutideefficacy in treatment of Type 2 diabetes, obesity, heart failure, and chronic kidney failure, it emerges as important therapy in metabolic syndrome.

Physician's Lack Agreement – Patients Prefer Branded or Generic Drugs?

Physician's Lack Agreement – Patients Prefer Branded or Generic Drugs?

Generics are not widely used, despite cost advantage, due to a lack of information to patients and reluctance from physicians to prescribe generics - A Need to educate masses

Drug Resistant Melanoma Caused Due to Break in Genes!

Drug Resistant Melanoma Caused Due to Break in Genes!

Studies have led to discovery that drug-resistant melanomas are caused by breaks in the genes, thereby leading to emphasis on alternate targeted therapies to combat cancer.

Advertisement